---
title: 'BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: Efficacy,
  safety and resistance mechanisms'
date: '2024-01-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38194680/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240110170437&v=2.18.0
source: Blood
description: Bispecific antibodies that engage T cells to target B cell maturation
  antigen (BCMA) or G protein-coupled receptor class C group 5 member D (GPRC5D) have
  demonstrated remarkable efficacy in heavily pretreated relapsed or refractory MM
  leading to the recent accelerated approval of teclistamab, elranatamab and talquetamab
  by health agencies. Future challenges however remain to define their optimal dosing
  schedule and duration, sequencing and integration with established anti-MM therapeutics
  ...
disable_comments: true
---
Bispecific antibodies that engage T cells to target B cell maturation antigen (BCMA) or G protein-coupled receptor class C group 5 member D (GPRC5D) have demonstrated remarkable efficacy in heavily pretreated relapsed or refractory MM leading to the recent accelerated approval of teclistamab, elranatamab and talquetamab by health agencies. Future challenges however remain to define their optimal dosing schedule and duration, sequencing and integration with established anti-MM therapeutics ...